Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

Cancer Science

Volumn 94, Issue 6, 2003, Pages 557-563

  Mukai, Motoi ^a,b   Che, Xiao Fang ^a   Furukawa, Tatsuhiko ^a   Sumizawa, Tomoyuki ^a   Aoki, Shunji ^c   Ren, Xioa Qin ^a   Haraguchi, Misako ^a   Sugimoto, Yoshikazu ^d   Kobayashi, Motomasa ^c   Takamatsu, Hideo ^b   Akiyama, Shin Ichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (DIPHENYLMETHYL) 1 PIPERAZINYL] 5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINE CARBOXYLIC ACID P OXIDE; 5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; AMINOPYRIDINE DERIVATIVE; BCR ABL PROTEIN; CEPHARANTHINE; COLCHICINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRANLUKAST; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; PHILADELPHIA 1 CHROMOSOME; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL MEMBRANE; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; KB CELLS; LEUKEMIA, MYELOID, CHRONIC; LEUKOTRIENES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHOSPHORYLATION; PHOTOAFFINITY LABELS; PIPERAZINES; PYRIMIDINES; TYROSINE;

EID: 10744221573     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01482.x     Document Type: Article

References (35)

1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-84.
2. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta 1997; 1333: F201-16.
3. Skorska NM, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229-42.
4. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-8.
5. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-9.
6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
8. Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, Utsunomiya A, Arima T, Akiyama S. Expression of multidrug transuporter, P-glycoprotein, in chronic myelogenous leukemia cells in blast crisis. Br J Haematol 1990; 74: 24-9.
9. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
10. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629-35.
11. Shiraishi N, Shimada T, Kobayashi M, Kuwano M, Akiyama S. Effect of biscoclaurine alkaloids on multidrug-resistance in the KB human cancer cells. Cancer Res 1997; 47: 2413-6.
12. Nagayama S, Chen Z-S, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, Furukawa T, Aikou T, Akiyama S. Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett 1998; 130: 175-82.
13. Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K, Sakoda R, Akiyama S. Two pyridine analogues with more effective activity to reverse multidrug resistance and lower calcium channel bloking activity than their dihydropyridine counterparts. Cancer Res 1990; 50: 3055-61.
14. Baba M, Okamoto M, Kashiwada N, Ono M. Anti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells. Anti Chem 2002; 12: 307-12.
15. Aoki S, Yoshioka Y, Miyamoto YKH, Setiawan A, Murakami N, Chen Z, Sumizawa T, Akiyama S, Kobayashi M. Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp. Tetrahedron Lett 1998; 39: 6303-6.
16. Ren XQ. Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M, Chen Z, Kobayashi M, Akiyama S. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem 2001; 276: 23197-206.
17. Ueda K, Shimabuku AM, Konishi H, Fujii Y, Takebe S, Nishi K, Yoshida M, Beppu T, Komano T. Functional expression of human P-glycoprotein in Schizosaccharomyces pombe. FEBS Lett 1993; 330: 279-82.
18. Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K. Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 1997; 401: 11-4.
19. Cornwell MM, Gottesman MM, Pastan IH. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 1986; 261: 7921-8.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21. Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol 1982; 2: 881-9.
22. 4 receptor antagonist, ONO-1078. Cancer Lett 1998; 130: 175-82.
23. Okumura H, Chen ZS, Sakou M, Sumizawa T, Furukawa T, Komatsu M, Ikeda R, Suzuki H, Hirota K, Aikou T, Akiyama SI. Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. Mol Pharmacol 2000; 58: 1563-9.
24. 2+-dependent cardiac transport system for glutathione S-conjugates. A study using rat heart sarcolemma vesicles. J Biol Chem 1989; 264: 17343-8.
25. Ishikawa T, Ali Osman F. Glutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25.
26. Druker BJ, Sawyer CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capadeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
27. Gorre ME, Mohammed M, Ellwood K, Hsu H, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
28. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI 571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481-6.
29. Marx J. Cancer research. Why some leukemia cells resist STI-571. Science 2001; 292: 2231-3.
30. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91: 2415-22.
31. Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, Kurosawa M, Nakashima I. Cepharantine activates caspase and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem 2001; 82: 200-14.
32. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogeous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34.
33. Akiyama S, Yoshimura A, Kikuchi H, Sumizawa T, Kuwano M, Tahara Y. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells. Mol Pharmacol 1989; 36: 730-5.
34. Damiani D, Michieli M, Michelutti A, Fanin R, Russo D, Baccarani M. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. Leuk Lymphoma 1995; 17: 289-94.
35. Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 1994; 79: 200-4.